New blood pressure drug QLS1410 enters first human tests

NCT ID NCT07152444

Not yet recruiting Disease control Sponsor: Qilu Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial will test a new drug called QLS1410 in 78 healthy adults and people with mild high blood pressure. The main goal is to check safety and how the body processes the drug. Researchers will also look at how food affects the drug and whether it lowers blood pressure. This is a first step to see if the drug is safe enough for larger studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: QLS1410 (a drug that blocks an enzyme involved in blood pressure regulation)
What this could lead to: If successful, this could lead to a new treatment option for people with mild high blood pressure.
What could go wrong: This is a very early Phase 1 trial, so the main goal is safety, not effectiveness. The drug may not work as hoped or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MILD ESSENTIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential hypertension hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UNCONTROLLED HYPERTENSION

Contacts and locations

Locations

Peking University Third Hospital

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.